Almirall and Forest Laboratories announce positive results of a Phase III Study for aclidinium and formoterol combination in COPD
2013-04-16 · Almirall, S.A. · original almirall.com ↗
Aclidinium / formoterol fixed dose combinations twice daily show statistically significant improvements in the two co-primary endpoints in the first pivotal COPD study A second pivotal Phase III study is still ongoing, results expected in coming weeks Barcelona and New York, April 16th, 2013 - Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from a six month pivotal phase III clinical trial evaluating the efficacy and safety of fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) delivered by Almirall's inhaler Genuair® (Pressair™ in the USA).
The release as fetched from its publisher. almirall.com ↗